An oral drug just grew 30 extra hairs per square centimetre. Here is what that tells us about where hair loss actually lives.

The dominant model of hair loss treatment for the past thirty years has been topical: apply something to the scalp, hope it reaches the follicle, measure what happens. Minoxidil is rubbed in twice daily. Finasteride is systemic but was developed as a prostate drug. The thinking has been that hair loss happens on the scalp, so the scalp is where you treat it.

Veradermics just published Phase 3 results for a pill.

VDPHL01, taken orally once or twice daily, produced 30 to 33 additional hairs per square centimetre over six months in trial participants. The placebo group grew approximately seven. That gap — 30 versus 7, achieved through systemic delivery — is one of the cleaner efficacy signals in recent hair loss trial data. And the most significant thing about it is not the number. It is the route.

Why Oral Matters

What systemic delivery says about where hair loss lives.

A topical treatment operates on the assumption that the problem is local — that the follicle needs something applied to it directly, and the rest of the body is largely irrelevant. This model has always been incomplete. This week's research has mapped exactly why: the gut microbiome is causally linked to androgenetic alopecia. Cortisol stored in the hair shaft reflects months of systemic stress. Follicle dormancy is a cellular energy problem driven by mitochondrial metabolism. The scalp senescence cascade is driven by systemic inflammatory signals originating partly in the gut.

A drug that works when swallowed — that reaches the follicle through the bloodstream, through the same circulatory pathway that carries hormones, nutrients, inflammatory signals, and metabolic substrates — is confirming what the biology has been saying: the follicle is downstream of the whole body. Treating it locally while the systemic drivers continue unaddressed is like mopping the floor without turning off the tap.

The Botanical Parallel

The systemic delivery route that has always been available.

Laritelle has always been built around the premise that the follicle is downstream of the whole body — that what reaches it through the blood matters as much as what is applied to the surface. This is why the formulas address hormonal balance, circulation, cortisol, and the inflammatory environment simultaneously. It is why the daily scalp ritual is structured as a whole-body intervention delivered through the most intimate and repeatable act available.

The oral drug confirms the premise. It does not replace the approach.

The Honest Assessment

What VDPHL01 is — and what it still requires.

The Phase 3 result is strong. An oral drug producing double the minoxidil result at six months, through a systemic delivery route, with a cleaner trial signal than most hair loss pharmaceuticals have produced, is genuinely significant progress.

What remains unknown: the mechanism, the long-term safety profile, the rebound question (does hair loss return when the drug is stopped, as it does with minoxidil?), the cost and accessibility once approved, and whether the results replicate in women — who, as the million-user dataset confirmed, represent the majority of those affected by hair loss but are consistently undertrialled in hair loss pharmaceutical research.

VDPHL01 will not be available by prescription this year. Regulatory approval, if it proceeds, is likely 18 to 24 months away at minimum. The systemic approach it validates, however, is available today — through every daily practice that changes what the blood carries to the follicle.